2022 AIMBE Fellow
2022 AIMBE Fellow
Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”
AIMBE Fellows are among the most distinguished medical and biological engineers including 3 Nobel Prize laureates, 18 Fellows having received the Presidential Medal of Science and/or Technology and Innovation, and 201 also inducted to the National Academy of Engineering, 101 inducted to the National Academy of Medicine and 45 inducted to the National Academy of Sciences.
Fraley’s team works on developing diagnostic technologies to achieve simple yet comprehensive infectious disease screening and identification. In clinical samples, detecting pathogens can be a needle in a haystack problem. By integrating mechanical, electrical and biomolecular engineering approaches along with imaging and machine learning techniques, Fraley and her team have developed innovative technologies that will not only advance patient care, but also generate new insights into research on heterogeneous microbial populations.
Fraley’s work also aims to understand how living cells migrate in reliable and orchestrated ways. Cell migration is a complex behavior that emerges from the interactions of tens of thousands of molecular pieces. Today, most of the knowledge of cell migration is confined to artificial 2D environments. Fraley and her team develop quantitative microscopy and imaging techniques, engineer 3D matrices and engage in molecular engineering to bring cell migration research into the third dimension. Applications include therapies for metastatic cancer cells.